JAMA Netw Open:母亲宫颈疾病与后代人乳头瘤病毒疫苗接种的关系

2022-01-05 从医路漫漫 MedSci原创

众所周知,儿童接种疫苗可预防的疾病(如人类乳头瘤病毒(HPV)引起的疾病)是众所周知的。

重要性:众所周知,儿童接种疫苗可预防的疾病(如人类乳头瘤病毒(HPV)引起的疾病)是众所周知的。然而,显著性偏倚(随着对结果的熟悉程度的提高,人们对风险的认知发生了改变)在决定为儿童接种疫苗方面的作用尚未得到明确的研究。

目的:评估父母对儿童接种疫苗的决定是否存在显著性偏差。

设计、设置和参与者:本回顾性队列研究采用时间到事件(生存)分析,比较了母亲有宫颈癌或宫颈活检史、经过疫苗接种可预防不良结果、以及疫苗接种对这些儿童的接种率。对照组孩子的母亲没有这样的病史。参与者来自MarketScan商业数据库,包括从2014年1月1日至2018年12月31日满11岁的美国儿童,当时建议接种HPV疫苗。分析了2020年12月29日至2021年9月17日的数据。

暴露史:母亲有宫颈癌或宫颈活检病史。

主要成果和措施:疫苗接种人乳头状瘤病毒。

结果:共检出儿童757 428例,其中女童370 878例[49.0%],男童386 550例[51.0%],母亲有单纯宫颈活检史的儿童38 366例,母亲有宫颈癌史的儿童1084例。总的来说,54.2%的儿童(55.7%的女孩和52.7%的男孩)在16岁之前至少接种了一次疫苗。在一项事件时间分析中,HPV疫苗接种在母亲患有宫颈癌的儿童和母亲未患宫颈癌的儿童之间没有差异(女孩的风险比[HR], 0.99 [95% CI, 0.86-1.13];男孩的HR, 1.08[95%可信区间,0.94-1.24])。母亲的宫颈活检史与最低限度增加的疫苗接种风险相关(女孩的HR, 1.06 [95% CI, 1.04-1.09];男孩的HR, 1.04[95%可信区间,1.01-1.06])。破伤风/白喉/非细胞性百日咳和脑膜炎球菌疫苗接种组之间没有临床意义的差异,这也是在11岁时推荐的。

图1 人乳头瘤病毒(HPV)首次疫苗接种时间的Kaplan-Meier曲线,按性别、宫颈癌和活检病史分层

表 Cox比例风险回归模型

第二次人乳头瘤病毒(HPV)疫苗接种时间的Kaplan-Meier曲线,按性别、宫颈癌病史和活检进行分层

结论:在这项儿童疫苗接种决定的显著性偏倚分析中,母亲的个人宫颈癌或宫颈活检病史与儿童HPV疫苗较高的接种率无关。这项时间-事件队列研究的结果表明,母亲有宫颈癌或需要活检的宫颈异常病史的儿童不太可能给他们的孩子接种HPV疫苗,尽管他们经历过疫苗可以预防不良后果。这些发现还表明,有不良宫颈结局史的母亲可能不知道HPV和宫颈疾病之间的因果关系,需要进一步的研究来了解父母的决定与不良的个人经历、对其致病因素的了解以及其他因素(如政治信仰)之间的关系,这些因素可能对疫苗接种的决定有更大的影响。

原文出处:

 Worsham CM,  Woo J,  Zimerman A,  Bray CF,  Jena AB,Association of Maternal Cervical Disease With Human Papillomavirus Vaccination Among Offspring.JAMA Netw Open 2021 Dec 01;4(12)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1755314, encodeId=e0d61e5531466, content=<a href='/topic/show?id=64572463895' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24638, encryptionId=64572463895, topicName=人乳头瘤病毒疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b33b36855486, createdName=saikp, createdTime=Sun May 01 03:18:53 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083472, encodeId=3aad20834e2fb, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Sun Sep 18 12:18:53 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734448, encodeId=5c801e3444890, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Oct 07 01:18:53 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729272, encodeId=0f5b1e292729d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 29 14:18:53 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185985, encodeId=233c1185985fc, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220625/6f4f075937de4c5d9fc7ab3a1bc6d8c2/13a8a29e67044698af1fb74276589093.jpg, createdBy=b5c55099112, createdName=D-House, createdTime=Wed Jan 19 12:48:14 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258132, encodeId=e3e2125813273, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408339, encodeId=0b3f1408339ba, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443505, encodeId=44dc1443505d8, content=<a href='/topic/show?id=4a65246327c' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24632, encryptionId=4a65246327c, topicName=人乳头瘤病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb15077773, createdName=ms3297076796458174, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490444, encodeId=41f114904441d, content=<a href='/topic/show?id=87b22463ed6' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24637, encryptionId=87b22463ed6, topicName=人乳头瘤病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8128741577, createdName=hyf031, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1755314, encodeId=e0d61e5531466, content=<a href='/topic/show?id=64572463895' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24638, encryptionId=64572463895, topicName=人乳头瘤病毒疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b33b36855486, createdName=saikp, createdTime=Sun May 01 03:18:53 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083472, encodeId=3aad20834e2fb, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Sun Sep 18 12:18:53 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734448, encodeId=5c801e3444890, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Oct 07 01:18:53 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729272, encodeId=0f5b1e292729d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 29 14:18:53 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185985, encodeId=233c1185985fc, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220625/6f4f075937de4c5d9fc7ab3a1bc6d8c2/13a8a29e67044698af1fb74276589093.jpg, createdBy=b5c55099112, createdName=D-House, createdTime=Wed Jan 19 12:48:14 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258132, encodeId=e3e2125813273, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408339, encodeId=0b3f1408339ba, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443505, encodeId=44dc1443505d8, content=<a href='/topic/show?id=4a65246327c' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24632, encryptionId=4a65246327c, topicName=人乳头瘤病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb15077773, createdName=ms3297076796458174, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490444, encodeId=41f114904441d, content=<a href='/topic/show?id=87b22463ed6' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24637, encryptionId=87b22463ed6, topicName=人乳头瘤病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8128741577, createdName=hyf031, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1755314, encodeId=e0d61e5531466, content=<a href='/topic/show?id=64572463895' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24638, encryptionId=64572463895, topicName=人乳头瘤病毒疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b33b36855486, createdName=saikp, createdTime=Sun May 01 03:18:53 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083472, encodeId=3aad20834e2fb, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Sun Sep 18 12:18:53 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734448, encodeId=5c801e3444890, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Oct 07 01:18:53 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729272, encodeId=0f5b1e292729d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 29 14:18:53 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185985, encodeId=233c1185985fc, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220625/6f4f075937de4c5d9fc7ab3a1bc6d8c2/13a8a29e67044698af1fb74276589093.jpg, createdBy=b5c55099112, createdName=D-House, createdTime=Wed Jan 19 12:48:14 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258132, encodeId=e3e2125813273, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408339, encodeId=0b3f1408339ba, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443505, encodeId=44dc1443505d8, content=<a href='/topic/show?id=4a65246327c' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24632, encryptionId=4a65246327c, topicName=人乳头瘤病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb15077773, createdName=ms3297076796458174, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490444, encodeId=41f114904441d, content=<a href='/topic/show?id=87b22463ed6' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24637, encryptionId=87b22463ed6, topicName=人乳头瘤病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8128741577, createdName=hyf031, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=)]
    2022-10-07 canlab
  4. [GetPortalCommentsPageByObjectIdResponse(id=1755314, encodeId=e0d61e5531466, content=<a href='/topic/show?id=64572463895' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24638, encryptionId=64572463895, topicName=人乳头瘤病毒疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b33b36855486, createdName=saikp, createdTime=Sun May 01 03:18:53 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083472, encodeId=3aad20834e2fb, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Sun Sep 18 12:18:53 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734448, encodeId=5c801e3444890, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Oct 07 01:18:53 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729272, encodeId=0f5b1e292729d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 29 14:18:53 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185985, encodeId=233c1185985fc, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220625/6f4f075937de4c5d9fc7ab3a1bc6d8c2/13a8a29e67044698af1fb74276589093.jpg, createdBy=b5c55099112, createdName=D-House, createdTime=Wed Jan 19 12:48:14 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258132, encodeId=e3e2125813273, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408339, encodeId=0b3f1408339ba, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443505, encodeId=44dc1443505d8, content=<a href='/topic/show?id=4a65246327c' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24632, encryptionId=4a65246327c, topicName=人乳头瘤病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb15077773, createdName=ms3297076796458174, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490444, encodeId=41f114904441d, content=<a href='/topic/show?id=87b22463ed6' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24637, encryptionId=87b22463ed6, topicName=人乳头瘤病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8128741577, createdName=hyf031, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=)]
    2022-11-29 feather89
  5. [GetPortalCommentsPageByObjectIdResponse(id=1755314, encodeId=e0d61e5531466, content=<a href='/topic/show?id=64572463895' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24638, encryptionId=64572463895, topicName=人乳头瘤病毒疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b33b36855486, createdName=saikp, createdTime=Sun May 01 03:18:53 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083472, encodeId=3aad20834e2fb, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Sun Sep 18 12:18:53 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734448, encodeId=5c801e3444890, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Oct 07 01:18:53 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729272, encodeId=0f5b1e292729d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 29 14:18:53 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185985, encodeId=233c1185985fc, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220625/6f4f075937de4c5d9fc7ab3a1bc6d8c2/13a8a29e67044698af1fb74276589093.jpg, createdBy=b5c55099112, createdName=D-House, createdTime=Wed Jan 19 12:48:14 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258132, encodeId=e3e2125813273, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408339, encodeId=0b3f1408339ba, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443505, encodeId=44dc1443505d8, content=<a href='/topic/show?id=4a65246327c' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24632, encryptionId=4a65246327c, topicName=人乳头瘤病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb15077773, createdName=ms3297076796458174, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490444, encodeId=41f114904441d, content=<a href='/topic/show?id=87b22463ed6' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24637, encryptionId=87b22463ed6, topicName=人乳头瘤病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8128741577, createdName=hyf031, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=)]
    2022-01-19 D-House

    积分

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1755314, encodeId=e0d61e5531466, content=<a href='/topic/show?id=64572463895' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24638, encryptionId=64572463895, topicName=人乳头瘤病毒疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b33b36855486, createdName=saikp, createdTime=Sun May 01 03:18:53 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083472, encodeId=3aad20834e2fb, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Sun Sep 18 12:18:53 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734448, encodeId=5c801e3444890, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Oct 07 01:18:53 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729272, encodeId=0f5b1e292729d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 29 14:18:53 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185985, encodeId=233c1185985fc, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220625/6f4f075937de4c5d9fc7ab3a1bc6d8c2/13a8a29e67044698af1fb74276589093.jpg, createdBy=b5c55099112, createdName=D-House, createdTime=Wed Jan 19 12:48:14 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258132, encodeId=e3e2125813273, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408339, encodeId=0b3f1408339ba, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443505, encodeId=44dc1443505d8, content=<a href='/topic/show?id=4a65246327c' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24632, encryptionId=4a65246327c, topicName=人乳头瘤病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb15077773, createdName=ms3297076796458174, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490444, encodeId=41f114904441d, content=<a href='/topic/show?id=87b22463ed6' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24637, encryptionId=87b22463ed6, topicName=人乳头瘤病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8128741577, createdName=hyf031, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1755314, encodeId=e0d61e5531466, content=<a href='/topic/show?id=64572463895' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24638, encryptionId=64572463895, topicName=人乳头瘤病毒疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b33b36855486, createdName=saikp, createdTime=Sun May 01 03:18:53 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083472, encodeId=3aad20834e2fb, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Sun Sep 18 12:18:53 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734448, encodeId=5c801e3444890, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Oct 07 01:18:53 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729272, encodeId=0f5b1e292729d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 29 14:18:53 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185985, encodeId=233c1185985fc, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220625/6f4f075937de4c5d9fc7ab3a1bc6d8c2/13a8a29e67044698af1fb74276589093.jpg, createdBy=b5c55099112, createdName=D-House, createdTime=Wed Jan 19 12:48:14 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258132, encodeId=e3e2125813273, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408339, encodeId=0b3f1408339ba, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443505, encodeId=44dc1443505d8, content=<a href='/topic/show?id=4a65246327c' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24632, encryptionId=4a65246327c, topicName=人乳头瘤病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb15077773, createdName=ms3297076796458174, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490444, encodeId=41f114904441d, content=<a href='/topic/show?id=87b22463ed6' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24637, encryptionId=87b22463ed6, topicName=人乳头瘤病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8128741577, createdName=hyf031, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=)]
    2022-01-07 一闲
  8. [GetPortalCommentsPageByObjectIdResponse(id=1755314, encodeId=e0d61e5531466, content=<a href='/topic/show?id=64572463895' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24638, encryptionId=64572463895, topicName=人乳头瘤病毒疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b33b36855486, createdName=saikp, createdTime=Sun May 01 03:18:53 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083472, encodeId=3aad20834e2fb, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Sun Sep 18 12:18:53 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734448, encodeId=5c801e3444890, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Oct 07 01:18:53 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729272, encodeId=0f5b1e292729d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 29 14:18:53 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185985, encodeId=233c1185985fc, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220625/6f4f075937de4c5d9fc7ab3a1bc6d8c2/13a8a29e67044698af1fb74276589093.jpg, createdBy=b5c55099112, createdName=D-House, createdTime=Wed Jan 19 12:48:14 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258132, encodeId=e3e2125813273, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408339, encodeId=0b3f1408339ba, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443505, encodeId=44dc1443505d8, content=<a href='/topic/show?id=4a65246327c' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24632, encryptionId=4a65246327c, topicName=人乳头瘤病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb15077773, createdName=ms3297076796458174, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490444, encodeId=41f114904441d, content=<a href='/topic/show?id=87b22463ed6' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24637, encryptionId=87b22463ed6, topicName=人乳头瘤病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8128741577, createdName=hyf031, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1755314, encodeId=e0d61e5531466, content=<a href='/topic/show?id=64572463895' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24638, encryptionId=64572463895, topicName=人乳头瘤病毒疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b33b36855486, createdName=saikp, createdTime=Sun May 01 03:18:53 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083472, encodeId=3aad20834e2fb, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Sun Sep 18 12:18:53 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734448, encodeId=5c801e3444890, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Fri Oct 07 01:18:53 CST 2022, time=2022-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729272, encodeId=0f5b1e292729d, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 29 14:18:53 CST 2022, time=2022-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185985, encodeId=233c1185985fc, content=积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220625/6f4f075937de4c5d9fc7ab3a1bc6d8c2/13a8a29e67044698af1fb74276589093.jpg, createdBy=b5c55099112, createdName=D-House, createdTime=Wed Jan 19 12:48:14 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258132, encodeId=e3e2125813273, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408339, encodeId=0b3f1408339ba, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443505, encodeId=44dc1443505d8, content=<a href='/topic/show?id=4a65246327c' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24632, encryptionId=4a65246327c, topicName=人乳头瘤病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fb15077773, createdName=ms3297076796458174, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490444, encodeId=41f114904441d, content=<a href='/topic/show?id=87b22463ed6' target=_blank style='color:#2F92EE;'>#人乳头瘤病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24637, encryptionId=87b22463ed6, topicName=人乳头瘤病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d8128741577, createdName=hyf031, createdTime=Fri Jan 07 13:18:53 CST 2022, time=2022-01-07, status=1, ipAttribution=)]

相关资讯

Front Immunol:COVID-19疫苗相关血栓形成的关系

目前使用两种不同的技术开发了两种类型的疫苗:病毒载体和mRNA。血栓形成是疫苗最严重、最不典型的不良反应之一。

武田收到美国FDA对TAK-721的完整回应函

该CRL指出,FDA已完成对TAK-721NDA的审核,确定该药不能以其目前的形式获得核准。此外,FDA建议追加一次临床研究,以帮助回应FDA的反馈。

JAMA Netw Open:COVID-19大流行前后韩国青年应激和自杀相关行为比较

COVID-19疫情已经影响到人类生活的方方面面,包括社会活动、教育和心理问题。COVID-19疫情对这些因素的影响因个人特征和社会环境的不同而不同。

JCEM:异体干细胞移植后代谢性疾病的发病率

异基因造血干细胞移植(Allogeneic hematopoietic stem cell transplantation,HRCT)是治疗各种恶性和非恶性血液病的一种重要的治疗方式。

Cardiovasc Diabetol:在退伍军人糖尿病试验(VADT)中,低空腹c肽水平与心血管风险、随访时血糖变化和严重低血糖相关

2型糖尿病的自然病史以不同的β细胞功能模式为特征。在疾病的早期阶段,β细胞功能相对保存良好,胰岛素分泌增加,这是克服胰岛素抵抗所需更高胰岛素水平的补偿要求的一部分。

Obes Rev:乳制品总摄入量与儿童和青少年超重和肥胖的关系

儿童肥胖已成为最严重的全球性问题之一。世界卫生组织(世卫组织)认识到这一点,并将儿童肥胖列为预防和控制慢性非传染性疾病2013-2020年全球行动计划的优先解决的问题。